A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system.
To determine the role of major histocompatibility complex (MHC) class I in immunological rejection of neural xenotransplants, F(ab')2 fragments of a monoclonal antibody to porcine MHC class I were used to mask this complex on porcine fetal striatal cells transplanted into rat striata previously lesioned with quinolinic acid. Presence of MHC class I on the surface of porcine striatal cells was confirmed by fluorescence-activated cell sorting prior to F(ab')2 treatment. At three to four months post-transplantation, survival of F(ab')2-treated xenografts was assessed by means of donor-specific immunostaining and compared to that of untreated xenografts in non-immunosuppressed rats and in rats immunosuppressed with cyclosporine A. In this study, masking of donor MHC class I by F(ab')2 treatment resulted in enhanced xenografts survival compared to the non-immunosuppressed controls (graft survival rates, 52% and 7%, respectively; P < 0.005) at survival times up to four months. While xenograft survival in F(ab')2-treated animals was not significantly different from that in cyclosporine-treated rats (74% graft survival), mean graft volume in F(ab')2-treated animals was smaller than that in cyclosporine-treated animals (1.07 +/- 0.30 mm3 versus 3.14 +/- 0.51 mm3; P < 0.005). The cytoarchitectonic organization of the xenografts was similar in F(ab')2- and cyclosporine-treated animals, and grafts in both groups exhibited long distance target-directed axonal outgrowth. The pattern of immunoreactivity to porcine MHC class I in the xenografts corresponded to the regional distribution of donor glia. In xenografts undergoing rejection, infiltration with host inflammatory cells was restricted to necrotic graft remnants and spared the nearby host structures. We conclude that MHC class-I-restricted immune mechanisms play an important role in neural xenograft rejection and that masking of this complex on donor cells may provide a useful strategy for immunoprotection of neural xenografts.
Pakzaban
P
P
Neurogeneration Laboratory, McLean Hospital, Belmont, MA 02178, USA.
Deacon
T W
TW
Burns
L H
LH
Dinsmore
J
J
Isacson
O
O
D000818:Animals; D001369:Axons / Q000187:drug effects / Q000648:ultrastructure; D016380:Brain Tissue Transplantation / Q000276:immunology* / Q000502:physiology; D017690:Cell Transplantation / Q000502:physiology*; D016572:Cyclosporine / Q000494:pharmacology; D016332:Fetal Tissue Transplantation / Q000276:immunology* / Q000502:physiology; D005724:Ganglia / Q000166:cytology; D006085:Graft Survival / Q000276:immunology* / Q000502:physiology; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism; D007150:Immunohistochemistry; D007165:Immunosuppression Therapy; D008285:Major Histocompatibility Complex / Q000276:immunology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology* / Q000502:physiology
D007140:Immunoglobulin Fab Fragments; D016572:Cyclosporine